Objective: To determine whether rheumatoid factor (RF), anti-CCP antibodies, or carriage of shared epitope (SE) and PTPN22 genetic susceptibility variants predict response to therapy in patients with rheumatoid arthritis (RA) treated with anti-TNF agents.
Methods: UK-wide multi-centre collaborations were established to recruit a large cohort of patients treated with anti-TNF drugs for RA. Serum RF, anti-CCP antibody and SE status were determined using commercially available kits. PTPN22 R620W genotyping was performed by Sequenom MassArray®. Linear regression analyses were performed to investigate the role of these 4 factors in predicting response to treatment by 6 months, defined as the absolute change in DAS28.
Results: Of the 642 patients analysed, 46% received infliximab, 43% etanercept and 11% adalimumab. 89% and 82% of patients were RF and anti-CCP positive, respectively. RF negative patients had a 0.48 (95% CI: 0.08, 0.87) greater mean improvement in DAS28 compared to RF positive patients. A better response was also seen among anti-CCP negative patients. No association was demonstrated between drug response and SE or PTPN22 620W carriage.
Conclusion: The presence of RF or anti-CCP antibodies was associated with a reduced response to anti-TNF drugs. However, these antibodies only account for a small proportion of the variance in treatment response. It is likely that genetic factors will contribute to treatment response, but these do not include the well-established RA susceptibility loci, SE and PTPN22.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.